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Abstract: Current risk factors in stage II colorectal carcinoma are
insufﬁcient to guide treatment decisions. Loss of CDX2 has been
shown to associate with poor clinical outcome and predict beneﬁt
for adjuvant chemotherapy in stage II and III colorectal carcino-
ma. The prognostic relevance of CDX2 in stage II disease has not
been sufﬁciently validated, especially in relation to clinical risk
factors, such as microsatellite instability (MSI) status, BRAF
mutation status, and tumor budding. In this study, we evaluated
the protein expression of CDX2 in tumor center and front areas in
a tissue microarrays material of stage II colorectal carcinoma
patients (n= 232). CDX2 expression showed a partial or total
loss in respective areas in 8.6% and 10.9% of patient cases. Patients
with loss of CDX2 had shorter disease-speciﬁc survival when
scored independently either in tumor center or tumor front
areas (log rank P= 0.012; P= 0.012). Loss of CDX2 predicted
survival independently of other stage II risk factors, such as MSI
status and BRAF mutation status, pT class, and tumor budding
(hazard ratio= 5.96, 95% conﬁdence interval= 1.55-22.95; hazard
ratio= 3.70, 95% conﬁdence interval= 1.30-10.56). Importantly,
CDX2 loss predicted inferior survival only in patients with mi-
crosatellite stable, but not with MSI-high phenotype. Interestingly,
CDX2 loss associated with low E-cadherin expression, tight junc-
tion disruption, and high expression of ezrin protein. The work
demonstrates that loss of CDX2 is an independent risk factor of
poor disease-speciﬁc survival in stage II colorectal carcinoma.
Furthermore, the study suggests that CDX2 loss is linked with
epithelial-to-mesenchymal transition independently of tumor bud-
ding.
Key Words: CDX2, stage II colorectal cancer, microsatellite in-
stability, tumor budding, epithelial-to-mesenchymal transition
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Colorectal carcinoma is one of the most common ma-lignant neoplasms, especially in the countries of the
Western world, and its incidence is still increasing.1 Its
prognosis has gradually improved with the development
of diagnostics, improved treatment of the disease, and the
advent of multidisciplinary teams.2 In stage I disease, local
excision or resection is sufﬁcient treatment, and no ad-
juvant chemotherapy is needed.3 In stage III disease, pa-
tients clearly beneﬁt from adjuvant treatment, which has
been shown to markedly reduce the risk of recurrent
disease.4 In addition, the treatment options for stage IV
disease have widened during the last years, especially with
the coming of biological treatments, such as anti-EGFR
and anti-VEGF treatments, but also by the development
of the surgical techniques to remove solitary metastases
from the liver and/or lung.5 However, stage II colorectal
carcinoma remains a problem in terms of selecting optimal
treatment. Although many risk factors for recurrence in
stage II disease have been identiﬁed, such as lymphovas-
cular invasion, perineural invasion, preoperative ob-
struction, preoperative perforation, T4 disease, and <12
lymph nodes examined, a considerable number of patients
do suffer relapse without any of these current risk factors.6
Thus, new biomarkers are needed to identify stage II
colorectal carcinoma patients at risk of relapse.
Lately, new promising biomarkers have been identiﬁed
to risk stratify stage II colorectal carcinoma patients. These
include microsatellite instability (MSI) status,7 tumor
budding,8 immunoscore,9 and the consensus molecular
subtyping,10 from which the MSI and tumor budding have
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been accepted as additional prognostic factors of stage II col-
orectal carcinoma in TNM8 classiﬁcation.11 In our previous
studies, we have shown the combined ability ofMSI status and
ezrin protein expression, and tumor budding grade, to pick up
high-risk stage II colorectal carcinoma patients.12,13 Moreover,
several other biomarkers have been documented to better
stratify the risk of relapse in stage II colorectal carcinoma.14 Of
them, CDX2 shows up as one of the most promising candi-
dates for further analysis and validation.
CDX2 is a caudal-type homeobox transcription factor,
which has a crucial effect on the development, differentiation,
and maintenance of colonic epithelium.15 It orchestrates
a gene regulatory network responsible for generating epi-
thelial apical-to-basal polarity in embryonic blastocysts16,17
and in mouse enterocytes and human colonic epithelial
cells.18 CDX2 has been suggested to possess tumor-sup-
pressing functions by governing several genes responsible for
proliferation, migration, and carcinogenesis.19 CDX2 stain-
ing has been used for years in clinical pathology as a marker
of intestinal differentiation, and it shows positive nuclear
staining in the large majority (>90% to 100 %) of colorectal
and appendix adenocarcinomas.20 CDX2 expression is often
lost in colorectal carcinomas with high tumor grade, ad-
vanced tumor stage, BRAF mutation, MSI-high phenotype,
and with poor prognosis.21,22 Recently, the loss of CDX2
protein expression was found to associate with poor prog-
nosis of stage II colon cancer.23,24 However, the prognostic
value of CDX2 loss has not been studied in relation to MSI
status, BRAF mutation, and tumor budding in stage II col-
orectal carcinomas. Furthermore, as CDX2 is important in
epithelial cell polarity regulation, and its loss has been sug-
gested to associate with epithelial-to-mesenchymal transition
(EMT),25,26 it would be important to further investigate this
connection in colorectal carcinoma progression.
Ezrin, which is an ERM (ezrin-radixin-moesin) family
protein, links the plasma membrane and the actin cytoske-
leton to organize cellular morphology and cell signaling.27,28
In normal intestine, ezrin is necessary for maintaining epi-
thelial apical integrity and homeostasis.29 However, in-
creased ezrin protein expression has been shown to associate
with poor outcome in multiple malignancies30 including
colorectal carcinoma.13,31,32 Frose et al33 revealed ezrin as an
essential protein to mediate EMT and extravasation
by rearranging cytoskeleton and cell polarization in breast
cancer.
In this work, CDX2 protein expression was studied
in a cohort of stage II colorectal carcinoma patients, and
CDX2 staining pattern was compared with survival,
clinicopathologic variables, MSI status, BRAF mutation
status, tumor budding, ezrin expression, and with other
markers associated with epithelial junctional polarity and
EMT, such as E-cadherin (adherence junctions), Zonula
occludens 1 (ZO-1) (tight junctions), integrin beta 4
(ITGB4) (basement membrane), and cytokeratins.
MATERIALS AND METHODS
This study was implemented according to the RE-
MARK guidelines for reporting biomarker studies.34
Study Population
We collected archived parafﬁn-embedded tumor
material from consecutive stage II CRC patients operated
in Turku University Hospital during the period spanning
from 2005 to 2012. This study was approved by the Chief
Executive Ofﬁcer of TYKS-SAPA, Hospital District of
Southwest Finland (T52/2014). The use of tissue material
was approved by the Scientiﬁc Steering Group of Auria
Biobank (AB15-8108, 25.5.2012). The study was conducted
in accordance with the Declaration of Helsinki. The clinical
data were retrieved and histological samples collected and
analyzed with the endorsement of the National Authority
for Medico-Legal Affairs (VALVIRA, (Dnro 4423/32/300/
02). The patient records were accessed anonymously.
During the period spanning from 2005 to 2012, a
total of 232 stage II CRC patients were radically operated
in our hospital. Computed tomography (CT) of the
abdomen and chest x-ray or CT had been performed
preoperatively to rule out distant metastases. We carefully
checked the patient ﬁles, including surgery and pathology
reports, and excluded patients with veriﬁed lymph node or
distant metastases, those who had been operated upon
with palliative-intent surgery, and also patients with other
than adenocarcinoma histology (eg, neuroendocrine tu-
mors). Only patients with stage II CRC were included in
the current study. For tumor staging, TNM7 classiﬁcation
of malignant tumors35 was used. From the original cohort
(n= 232), for CDX2 evaluation, tumor center spots were
available from 209 patients and, for CDX2 staining con-
cerning tumor front spots, from 201 patients. The survival
analysis was made from both the tumor center and tumor
front spots separately. Of the total 232 stage II colorectal
carcinoma patients included in this study, 13 patients with
rectal carcinoma had received FU-based preoperative
chemotherapy and radiotherapy. Of these patients, CRM
was 0.5 mm or less among 7 patients.
Tissue Microarrays Construction
Tissue microarrays (TMA) were constructed and
analyzed using the next-generation TMA technique, and
the detailed methodology of this technique has been pre-
sented in a previous publication.13 The constructed TMA
blocks were sectioned, stained, scanned, and uploaded into
the web portal (casecenter.utu.ﬁ), and each individual spot
was scored either by a pathologist and senior scientist of
biomedicine (K.S., T.P.) or by 2 pathologists (K.S., J.S.).
In case of a discrepant result, a consensus score was
formed. The resulting scores were combined with the
clinical data for statistical analysis.
Immunohistochemistry
Immunohistochemical (IHC) stainings were performed
using standard procedures. Shortly, 3.5 µm sections were cut
and stained with monoclonal antibodies against MLH1
(Clone G168-15BD Pharmingen, dilution: 1:5), MSH2
(Clone G219-1129, BD Pharmingen, dilution: 1:200), and
MSH6 (Clone EP49, Epitomoc, dilution: 1:200). The signal
was detected with UltraView Universal DAB Detection kit.
For PMS2, Clone EPR3947 (Ventana/Roche, ready to use
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antibody) was used, and the signal was detected with Opti-
View Universal DABDetection Kit and ampliﬁcation kit. To
detect BRAF V600Emutation, BRAF RTU antibody (Clone
VE1, Roche/Ventana) was used, and the signal was detected
with OptiView Universal DAB Detection kit. For ezrin
staining, immunoglobulin G antibody to human ezrin (clone
3C12) was used. For CDX2 staining, CDX2 ready to use
antibody (clone EPR2764Y, Diagnostics, Roche) was used.
All the stainings were performed with BenchMark XT
(Ventana/Roche) using ultraVIEW Universal DAB De-
tection Kit (Ventana/Roche), except for ezrin, which was
carried out with LabVision immunoautomate (Thermo
Fisher Scientiﬁc) using the Power Vision Plus poly HRP
antimouse/rabbit/rat IgG detection kit.
For the epithelial polarity and EMT markers, a
multiplex IHC was performed, as described in a previous
study.12 The following antibodies were used. A combina-
tion of PanCk clones (C-11, ab7753, Abcam: 1 to 1500
and AE1/3, MA5-13156, Thermo Fisher Scientiﬁc In-
vitrogen: 1 to 1000), ZO-1 (CST, D7D12; 1 to 500),
ITGB4 (CST D8P63: 1 to 100), and ECADH (BD clone
36: 1 to 200) was used. The nuclei were stained using
DAPI (Roche, 5 µg/mL). ProLong Gold (Thermo Fisher
Scientiﬁc) was applied for coverslip mounting.
Evaluation of IHC Stainings
All IHC stainings were separately evaluated by 2 ob-
servers (K.S. and J.S. or K.S. and T.P.), blinded to clinical
data. CDX2 was evaluated, as it was in Dalerba et al,23 in the
following manner: loss of CDX2 equaled to total loss (initial
score 0) or weak/scattered staining in the minority of cells
(initial score 1). Conventional staining was given an initial
score of 2. Only nuclear staining was counted, and a score per
patient tumor center and tumor front was formed. As each
patient had 2 replicate TMA cores per tumor center and
tumor front, a ﬁnal score of the replicates was counted by
rounding the mean of replicates down as follows: 0 to 0.5=0
(negative), 1 to 1.5=1 (weak), and 2 (conventional). For ﬁnal
scores, 2 categories were used: negative/weak (CDX2 loss)
and conventional CDX2. Normal colonic mucosa TMA
spots were used as positive controls. MSI and BRAF V600E
mutation status and ezrin expression scores are from our
previous publication.13 Digital image analysis for E-cadherin,
ZO-1, ITGB4, and PanCk expression was carried out with
CellProﬁler 2.2.0. Each marker’s mean intensity (expression)
was measured within the epithelium compartment, and a
mean of tumor center and tumor front spots was counted as
described.12 For ﬁnal 2-tier scores, a dichotomization was
carried out on the basis of a median bin for each marker. The
analysis of tumor budding from HE-stained histologic whole
sections was performed according to the standards set by the
International Tumour Budding Consensus Conference
(ITBCC) 2016 and has been previously described.12
Statistical Analysis
For the association analyses, the 2-sided Fisher exact
or χ2 association test (χ2) was used as appropriate. Asso-
ciation analyses were carried out using IBM SPSS 24
(SPSS Inc., Armonk, NY). The Cox proportional hazard
regression model and the Kaplan-Meier analysis with log-
rank test for survival analysis were performed using R
version 3.4.3 (Foundation for Statistical Computing,
Vienna, Austria) and RStudio 1.1.383 (RStudio Inc.,
Boston, MA) with survival package 2.41-3. Proportional
hazard assumption was tested for each variable using
Schoenfeld test. The P-values in Cox regression analysis
were calculated using a Wald test.
RESULTS
CDX2 Association With Clinicopathologic
Variables and Survival
Clinicopathologic characteristics of the study cases
are summarized in Table 1. CDX2 nuclear staining from
tumor center spots was evaluable from 209 patients. Of
them, 18 (8.6 %) patients had a negative or weak/scattered
staining (loss of CDX2). Of tumor front spots, 22 (10.9 %)
of the evaluable 201 patient cases had a loss of CDX2
staining. There was a high correlation of CDX2 staining
between tumor center and tumor front cores across all the
patients (Spearman ρ= 0.809; P= 3.35E−47). Altogether,
7 patients had a different staining pattern with respect to
center and front cores. Representative images of CDX2
TABLE 1. Patient Characteristics





Median 74 R0 214
Range 34-96 R1 15
≤ 70 92 R2 3
> 70 140 Ln count
Sex ≥ 12 LNs collected 185
Female 117 < 12 LNs collected 47
Male 115 Vascular invasion
Tumor side No 179
Right side 112 Yes 39
Left side 120 ND 14
pT status Adjuvant chemo
T3N0 190 No 163
T4aN0 21 Yes 68
T4bN0 21 ND 1
Grade MSI status
G1 26 MSS 171
G2 154 MSI high 43
G3 51 ND 18
ND 1 BRAF status
Histology WT 183
Conventional 205 V600E 28
Mucinous 26 ND 21
ND 1 Neoadjuvant chemo+RT
Preoperative obstruction No 205
No 196 Yes 13





Chemo indicates chemotherapy; ND, not determined; RT, radiotherapy (rectal
carcinoma only).
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IHC are shown in Figure 1. Of the clinicopathologic
variables, tumor perforation and right-sided tumor
correlated with CDX2 loss (Table 2). Loss of CDX2 was
associated with shorter disease-free survival (DFS) and
disease-speciﬁc survival (DSS). None of the other
clinicopathologic variables (sex, age, pT status, tumor
grade, histologic type, vascular invasion, lymph node count,
radicality, preoperative obstruction, adjuvant chemotherapy,
or neoadjuvant chemoradiotherapy) correlated with CDX2
staining.
CDX2 Staining in Relation to Microsatellite
Stability and BRAF Mutation Status
The majority of patients with CDX2 loss in the tumor
center or tumor front had MSI-high phenotype (76% and
64%), while a minority of patients with conventional CDX2
staining were MSI high (15% and 16%). Among MSI-high
tumors, 13 of 42 (31%) had a loss of CDX2 in the tumor
center, while only 4 of 165 microsatellite stable (MSS) tu-
mors (2.4%) had a loss of CDX2. The results demonstrate
that CDX2 loss strongly associates with MSI-high pheno-
type (P< 0.001, Fisher exact test, Table 2).
BRAF mutation status correlated with CDX2
staining, although not as strongly as MSI status. The
frequency of BRAF-mutated tumors was 33% and 36%
among patients with CDX2 loss in the center or front,
respectively, while the mutation was present in 11% and
10% of patients with conventional CDX2 staining in tu-
mor center or front, respectively. Among 26 BRAF-mu-
tated tumors, 8 (31%) were CDX2 low, while, among 172
BRAF WT tumors, 14 (8 %) were CDX2 low in the tumor
front cores (P= 0.003, Fisher exact test, Table 2).
CDX2 Association With Markers of Epithelial
Polarity and EMT
Next, we investigated whether the loss of CDX2 as-
sociates with markers of epithelial integrity and polarity.
Loss of epithelial junctional and basement membrane
integrity, loss of apical-to-basal polarity, and tumor budding
are associated with EMT.36,37 In addition, ezrin, which is
a linker of the plasma membrane and cortical actin
cytoskeleton, has been recently implicated in the promotion
of metastasis through EMT.33 We found that CDX2 loss in
both tumor center and tumor front was associated with loss
of E-cadherin, but not with loss of other epithelial marker
expressions (ZO-1, ITGB4, PanCk), nor with tumor bud-
ding (Table 2). Consistent with the E-cadherin association,
CDX2 loss was also associated with loss of tight junction
integrity, as measured by ZO-1 perimeter (tight junction
perimeter) (Table 2). Interestingly, moderate to strong ezrin
protein expression was present in 94% and 95% of patients
with CDX2 loss in tumor center or tumor front cores,
respectively. Conversely, only one patient (1%) with CDX2
loss had low ezrin protein expression (P< 0.001, Pearson χ2
test). Of all the markers or clinicopathologic variables, the
association of CDX2 loss with high ezrin expression was the
most signiﬁcant.
CDX2 Loss as a Predictor of Poor Survival
Given the association of CDX2 loss with DFS and DSS,
we next performed prognosis analysis comparing patient
groups with conventional CDX2 staining and loss of CDX2.
Kaplan-Meier plots demonstrated that CDX2 loss was asso-
ciated with worse DSS when measured either in the tumor
center or tumor front TMA cores (P=0.012; P=0.012)
(Fig. 2). The prognostic effect was signiﬁcant also when
measuring DFS as the endpoint (P=0.004; P=0.005). Of the
MSS tumor patients with evaluable CDX2 (n=165), 50% of
the patients with CDX2 loss in either tumor center or tumor
front died of CRC (4/8 patients). Of the MSI-high tumor
patients, only 13% of the patients with CDX2 loss died of
CRC (2/15 patients). Accordingly, loss of CDX2 predicted
DSS and DFS only in the MSS patient group (P<0.001;
P=0.019), but not in the MSI-high group (P=0.21; P=0.14).
Examples of immunohistochemical staining patterns from a
patient with poor prognosis (loss of CDX2, MSS, BRAFmut,
FIGURE 1. Examples of CDX2 staining and scoring. CDX2 was visually evaluated with scores of 0, 1, and 2, representing total loss,
weak/scattered staining in minority of cells, and conventional staining, respectively. For subsequent analyses, patients were
dichotomized to CDX2 loss group (scores 0 and 1) and to conventional CDX2 group (score 2). Bar, 50 µm.
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TABLE 2. Association of CDX2 Expression (Center and Front) With Clinicopathologic Variables, Survival, and Markers Related to
Epithelial Integrity and EMT
CDX2 Expression
Center (N= 209), n (%) Front (N= 201), n (%) Cox Regression
Variable Low High Fisher Exact (P) Low High Fisher Exact (P) Univariate HR (95% CI)
Age (y) 1 1
≤ 70 (n= 85) 7 (3) 74 (36) 8 (4) 69 (34) 1 (ref)
> 70 (n= 135) 11 (5) 117 (56) 14 (7) 110 (55) 0.82 (0.39-1.75)
Sex 0.628 0.824
Female (n= 113) 8 (4) 98 (47) 12 (6) 92 (46) 1 (ref)
Male (n= 107) 10 (5) 93 (44) 10 (5) 87 (43) 0.89 (0.42-1.91)
Tumor side 0.012 0.024
Right (n= 108) 14 (7) 87 (41) 16 (8) 83 (41) 1 (ref)
Left (n= 112) 4 (2) 104 (50) 4 (3) 96 (48) 1.42 (0.66-3.05)
pT status 0.094 0.037
T3N0 (n= 178) 12 (6) 161 (77) 14 (7) 150 (75) 1 (ref)
T4abN0 (n= 42) 6 (3) 30 (14) 8 (4) 29 (14) 3.02 (1.38-6.62)
Grade 0.134 0.179
G1-2 (n= 169) 11 (6) 151 (72) 14 (7) 140 (70) 1 (ref)
G3 (n= 50) 7 (3) 40 (19) 8 (4) 39 (19) 1.00 (0.40-2.47)
Histology 0.701 0.732
Conventional (n= 193) 17 (8) 168 (80) 19 (9) 158 (79) 1 (ref)
Mucinous (n= 26) 1 (1) 23 (11) 3 (2) 21 (10) 0.69 (0.16-2.91)
Preoperativeobstruction 0.286 1
No (n= 186) 14 (7) 166 (79) 19 (9) 154 (77) 1 (ref)
Yes (n= 34) 4 (2) 25 (12) 3 (2) 25 (12) 1.58 (0.64-3.91)
Perforation 0.001 0.003
No (n= 203) 12 (6) 181 (87) 16 (8) 168 (84) 1 (ref)
Yes (n= 18) 6 (3) 9 (4) 6 (3) 10 (5) 4.39 (1.76-10.95)
Radicality 0.624 0.655
R0 (n= 203) 16 (8) 178 (85) 20 (10) 167 (83) 1 (ref)
R1-2 (n= 17) 2 (1) 13 (6) 2 (1) 12 (6) 0.59 (0.08-4.37)
Ln count 0.132 0.577
≥ 12 LNs (n= 175) 17 (8) 150 (72) 19 (10) 142 (70) 1 (ref)
< 12 LNs (n= 45) 1 (1) 41 (19) 3 (2) 37 (18) 1.57 (0.69-3.60)
Vascular invasion 0.745 0.568
No (n= 171) 15 (7) 145 (74) 16 (8) 136 (72) 1 (ref)
Yes (n= 37) 2 (1) 35 (18) 5 (3) 32 (17) 2.10 (0.92-4.80)
Adj chemo 0.093 0.322
No (155) 8 (4) 51 (25) 8 (4) 50 (25) 1 (ref)
Yes (64) 9 (4) 140 (67) 13 (6) 129 (65) 1.57 (0.73-3.38)
MSI status 2.4E−07 4.0E−06
MSS (n= 165) 4 (2) 161 (78) 8 (4) 150 (75) 1 (ref)
MSI high (n= 42) 13 (6) 29 (14) 14 (7) 28 (14) 0.52 (0.16-1.75)
Neoadjuvant chemo+RT 0.196 0.205
No (n= 215) 15 (7) 180 (88) 19 (10) 170 (86) 1 (ref)
Yes (n= 13) 2 (1) 8 (4) 2 (1) 6 (3) 0.61 (0.08-4.50)
BRAF status 0.014 0.003
WT (n= 183) 12 (6) 169 (81) 14 (7) 158 (80) 1 (ref)
V600E (n= 28) 6 (3) 20 (10) 8 (4) 18 (9) 0.61 (0.14-2.61)
Tumor budding 0.139 0.313
Low Bd < 7 (196) 14 (7) 169 (81) 18 (9) 157 (79) 1 (ref)
High Bd ≥ 7 (24) 4 (2) 20 (10) 4 (2) 20 (10) 7.55 (3.39-16.84)
DFS 0.017 0.019
No event (182) 12 (6) 170 (81) 15 (7) 158 (79) NA
Event (27) 6 (3) 21 (10) 7 (4) 21 (10) NA
DSS 0.033 0.033
No event (186) 13 (6) 173 (83) 16 (8) 161 (8) NA
Event (23) 5 (2) 18 (9) 6 (3) 18 (9) NA
ITGB4 0.081 0.011
Low (n= 110) 5 (2) 100 (48) 5 (2) 95 (47) 1 (ref)
High (n= 106) 12 (6) 91 (44) 17 (9) 83 (42) 1.13 (0.52-2.48)
E-cadherin 0.040 0.040
Low (n= 107) 13 (6) 92 (44) 16 (8) 84 (42) 1 (ref)
High (n= 109) 4 (2) 99 (48) 6 (3) 94 (47) 0.96 (0.44-2.10)
PanCk 0.312 0.822
Low (n= 106) 6 (3) 97 (47) 10 (5) 89 (44) 1 (ref)
High (n= 110) 11 (5) 94 (45) 12 (6) 89 (45) 0.74 (0.33-1.62)
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strong ezrin) and from a patient with favorable prognosis
(conventional CDX2, MSI high, BRAFwt, weak ezrin) are
shown in Figure 3. The prognostic signiﬁcance of CDX2 loss
remained after adjusting for other confounding risk factors in a
multivariate cox regression model when CDX2 was scored
either in the tumor center or tumor front (hazard ratio=5.96,
95% conﬁdence interval=1.55-22.95; hazard ratio=3.70, 95%
conﬁdence interval=1.30-10.56) (Table 3). Risk factors in the
model included were depth of invasion (pT3 vs. pT4) of the
primary tumor, number of lymph nodes resected at surgery
(≥12 vs. <12), tumor side (left vs. right), tumor perforation
(no vs. yes), MSI status (MSI vs. MSS), BRAF mutation (no
vs. yes), vascular invasion (no vs. yes), and tumor budding (<7
vs. ≥7).
DISCUSSION
For over 20 years ago, caudal-type homeobox
transcription factor 2 (CDX2) was found with its highest
expression conﬁned to the intestinal epithelium.38 It be-
came a widely used tumor marker of intestinal origin in
clinical pathology, especially as part of a marker panel for
tumors of unknown primary origin.39 CDX2 is important
for gut development and homeostasis,40 but it also belongs
to tumor suppressor genes.41 For this reason, it is not
surprising that its downregulation is associated with high
tumor grade, lymphatic invasion, right-sided location,
more advanced stage, and poor prognosis.21,22,42,43 Re-
cently, the prognostic value of CDX2 loss was demon-
strated also in stage II colon cancer patients.23,24 In the
current study, we show poor DSS and DFS of stage II
patients with tumors bearing CDX2 loss, and correlation
of this staining pattern with MSI-high phenotype, BRAF
V600E mutation, right-sided tumor, tumor perforation,
low E-cadherin expression, and disruption of tight junc-
tions, and high ezrin protein expression.
The frequency of CDX2 loss in our study was 8.6%
and 10.9% in the center and front TMA spots,
respectively. This is very close to the previous reports in
stage II colorectal carcinomas using IHC as the readout.
Dalerba et al23 showed 13% and Hansen et al24 10%
frequency of CDX2−/weak cases. We used the same
scoring system as in the Dalerba et al study,23 wherein
CDX2 loss is equal to a complete lack of CDX2 ex-
pression or faint nuclear expression in a minority of ma-
lignant epithelial cells.
In this study, loss of CDX2 proved to be a risk factor
for poor DSS, both in univariate and multivariate analysis.
Given the relatively small fraction of patients with a loss of
CDX2 (around 10%), the study would have beneﬁted from
a larger cohort size. However, as an internal validation, the
same results were obtained when CDX2 was analyzed sep-
arately, either in the tumor center or tumor front cores. The
results also demonstrate that the prognostic value of CDX2
loss is independent on its spatial localization, although this
should be better validated using whole section analysis.
Previously, Dalerba and colleagues demonstrated that the
prognostic power of CDX2 loss was independent of other
confounding risk factors, which were age, pT status, and
grade.23 Similarly, Hansen et al24 showed prognostic in-
dependence of CDX2 loss from pT status, age, sex, vascular/
perineural invasion, and tumor perforation. However, nei-
ther of these 2 earlier studies with stage II material included
the MSI status, BRAF mutation status, or tumor budding
as risk factors in multivariate models. Our study demon-
strates that the prognostic value of CDX2 loss is in-
dependent also of these aforementioned risk factors in stage
II colorectal carcinoma.
We show that CDX2 loss correlated with MSI-high
phenotype, which is in concordance with several previous
studies.21,22,24,44 It has been reported, that MSI-high status
is linked with favorable prognosis in stage II colorectal
carcinoma,45 which is contradictory, as CDX2 loss also
associates with poor prognosis. Hansen et al24 showed that
CDX2 loss predicted clinical outcome in stage II patients
with MSI-high status. Here, in this work, we show that
TABLE 2. (continued)
CDX2 Expression
Center (N= 209), n (%) Front (N= 201), n (%) Cox Regression
Variable Low High Fisher Exact (P) Low High Fisher Exact (P) Univariate HR (95% CI)
ZO-1 0.312 0.822
Low (n= 108) 6 (3) 98 (47) 10 (5) 89 (44) 1 (ref)
High (n= 108) 11 (5) 93 (45) 12 (6) 89 (45) 1.76 (0.79-3.94)
TJ perimeter 0.023 0.023
Low (n= 108) 13 (6) 90 (43) 16 (8) 84 (42) 1 (ref)
High (n= 108) 4 (2) 101 (49) 6 (3) 94 (47) 0.94 (0.43-2.07)
Ezrin* 1.9E−08 2.0E−08
Low (n= 98) 1 (1) 93 (55) 1 (1) 90 (55) 1 (ref)
Intermediate (n= 36) 2 (1) 35 (21) 5 (3) 30 (18) 1.39 (0.42-4.62)
High (n= 38) 13 (8) 25 (14) 15 (9) 23 (14) 3.19 (1.19-8.54)
P-values are 2-sided exact signiﬁcances.
N-values in left column refer to the Cox regression analysis.
Bold values mark signiﬁcance, P< 0.05.
For HRs, P-values not shown.
*Pearson χ2 for ezrin instead of Fisher exact.
CI indicates conﬁdence interval; HR, hazard ratio, Cox regression univariate (DSS); NA, not applicable; ref, reference.
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CDX2 loss predicted worse outcome (DSS and DFS)
within the MSS patient group only, but not when analyzed
within the MSI-high patient group. This is in line with
recently published work,46 wherein it was demonstrated
that none of the patients with MSI-high and negative
CDX2 staining developed distant metastasis, while 75 %
of MSS patients with negative CDX2 had a metastasis.
Furthermore, Ryan et al47 showed that loss of CDX2 did
not associate with DFS in the mismatch repair–deﬁcient
(dMMR=MSI high) group of patients with heterogenous
stages (I to IV) (n= 238). Pilati et al48 further demon-
strated that lack of CDX2 was a prognostic factor only in
MSS and not in the MSI-high patient group of stage II
and III colon cancer. Overall, these results suggest that a
combination of MSS phenotype and loss of CDX2
stratiﬁes patients to worse survival outcome than that of
MSI-high phenotype and CDX2 loss.
The current work could demonstrate the correlation
between BRAF mutation and loss of CDX2, although the
correlation was not as strong as with MSI-high phenotype.
The association of negative CDX2 staining and BRAF
mutation has been reported in earlier publications.46,49–51
Bruun et al49 showed that CDX2 loss stratiﬁes stage I
to III colorectal patients to poor survival in a BRAF-
mutated subgroup. It has been hypothesized that the high
prevalence of BRAF mutation in CDX2− colorectal car-
cinoma develops through a serrated pathway,42 although
the exact functional mechanism of this correlation remains
to be elucidated.
Tumor budding, which is deﬁned by the presence
of single carcinoma cells or clusters of up to 4 cells at
the invasive front, is a risk factor for poor outcome
in stage II colorectal carcinoma.8,12 Many studies link
tumor budding with epithelial-to-mesenchymal transition
(EMT).12,37 In the current study, we found no correlation
of CDX2 with respect to tumor budding analyzed from
HE-stained whole sections, but we discovered a signiﬁcant
correlation between loss of CDX2 and low E-cadherin,
FIGURE 2. Loss of CDX2 predicts survival in stage II colorectal carcinoma. Kaplan-Meier plots with DSS probability (A, B) and DFS
probability (C, D) of patients with CDX2 loss (cyan, score 0) and with conventional CDX2 expression (red, score 1). Both the tumor
center (A, C) and tumor front cores (B, D) were analyzed separately. P-value is based on Log rank test. Values in brackets indicate
the number of events and the number of patients within each score group. HR indicates hazard ratio (univariate cox regression)
with *P<0.05 and **P<0.01.
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which is often lost during EMT. Some earlier studies
support the relationship between EMT and CDX2 ex-
pression. Pilati et al48 demonstrated that CDX2 loss is
prognostic only in a subgroup of patients with consensus
molecular subtype 4 (CMS4), which is linked to mesen-
chymal gene expression and TGFβ pathway activation.
Zhang et al26 demonstrated that forced CDX2 expression
induces E-cadherin and reverses EMT in gastric cancer. In
another study, it was shown that Claudin-1, which is an
important element of tight junctions, whose dysregulation
is implicated in EMT, is dependent on CDX2 regulation.25
In agreement with this study, we show here that CDX2
loss associates with disrupted epithelial tight junctions
(ZO-1 perimeter). Overall, these results suggest that loss of
CDX2 could functionally associate with EMT, but in-
dependently of tumor budding.
Ezrin is a member of the ERM (Ezrin, Radixin,
Moesin) complex, which links the actin cytoskeleton to
several membrane-associated receptors and adhesion
molecules.28 It plays a role in cell migration, proliferation,
survival, and signal transduction including mTOR, Pi3
kinase/Akt, Src, EGFR, Rho-kinase, and protein kinase C
pathways52 and, recently, was shown to mediate EMT and
extravasation.33 For this reason, it is not surprising that its
overexpression has been linked with poor outcome in
many malignancies including colorectal carcinoma.13,30–32
In the current study, we found a strong correlation be-
tween loss of CDX2 and high ezrin protein expression.
According to our knowledge, this association has not been
reported before, and it raises the question whether these
proteins could regulate each other. Both CDX2 and ezrin
play an important role in supporting apical junctional
integrity and cell polarity in embryogenesis16,17 and in
normal colonic epithelial cells.18 Recently, it was shown
that depletion of CDX2 resulted in diffuse E-cadherin
expression, reduced phosphorylated ezrin (p-ezrin), and
disrupted adherence junctions in blastocysts of porcine
embryos.16 Earlier, Gao and Kaestner18 demonstrated
that Cdx2 knock-out in mouse intestinal epithelium re-
sulted in signiﬁcant expression changes of 2 different
splicing variants of ezrin mRNA. These studies suggest a
model whereby CDX2 expression would be upstream of
ezrin expression. This could be, however, more compli-
cated, as a mutually reinforcing relationship between ep-
ithelial cell polarity and CDX2 expression has been
suggested.17 Further mechanistic studies are needed in
order to elaborate on the regulatory relationship of
CDX2, ezrin, and cell polarity and how this may affect
EMT and metastasis in colorectal carcinoma.
In conclusion, CDX2 loss is quite an infrequent event
in stage II colorectal carcinoma, but it is an independent risk
factor of poor DSS. The routine analysis of CDX2 staining
from stage II colorectal carcinoma patients, along with the
determination of MSI status and tumor budding grade,
might bring added value to identify high-risk patients
in need of adjuvant chemotherapy. However, this would
FIGURE 3. Example images of marker expressions in a colorectal carcinoma stage II patient case with poor survival (A–D) and with
favorable survival (E–H). The case with poor survival was CDX2 low, ezrin high, BRAF V600E+, and MSS (positive for MLH1, MSH2,
MSH6, and PMS2), whereas the case with favorable survival was CDX2 conventional, ezrin low, BRAF wt, and MSI high (MLH1−,
MSH2+, MSH6+, and PMS2−).
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require further validation and consensus of CDX2 scoring
criteria. In addition, the relationship of CDX2 loss with
EMT-related phenotypic changes (eg, low E-cadherin,
junctional disruption, high ezrin) warrants further inves-
tigation to ﬁnd out whether CDX2 is an active regulator or
a downstream target of EMT in colorectal carcinoma.
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